Overview A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers Status: Completed Trial end date: 2017-04-10 Target enrollment: Participant gender: Summary The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company